Introduction Patients with mild-to-moderate plaque psoriasis often experience reduced
quality of life and increased disease burden due to itch or involvement of psoriasis in special …

Introduction Psoriasis involvement in special areas (eg, scalp or nails) is associated with a
great disease burden yet it is often inadequately treated with topical treatments. The efficacy …

Background Patients with mild-to-moderate psoriasis may have substantial quality-of-life
impairment. Objective To evaluate apremilast 30 mg twice daily for mild-to-moderate …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Introduction The broad and sustained efficacy of apremilast for psoriasis has been
demonstrated in randomized and real-world observational studies. Data from Central and …

The introduction of several new therapeutic agents, predominantly biologic therapies, has
transformed the management of moderate and severe psoriasis in recent years. A novel oral …

Psoriasis is a chronic, inflammatory, immune‐mediated disease of the skin and joints.
Plaque psoriasis is the most common clinical phenotype of psoriasis. Apremilast is an oral …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …